MyFinsight
Home
Blog
About
Proceeds from issuance of
long-term debt, net
$46,030K
Proceeds from at the
market offering, net of...
$3,916K
Proceeds from exercise of
stock options
$398K
(48.51%↑ Y/Y)
Net cash provided by
(used in) financing...
$50,344K
(732.07%↑ Y/Y)
Other (income)
expense, net
$44,924K
Net change in cash,
cash equivalents,...
$28,965K
(155.47%↑ Y/Y)
Canceled cashflow
$21,379K
Net loss
$15,769K
(964.53%↑ Y/Y)
Accrued expenses and
other liabilities
$4,788K
(213.59%↑ Y/Y)
Loss on change in fair
value of embedded...
$4,535K
Stockbased compensation
expense
$2,083K
(-64.01%↓ Y/Y)
Depreciation and
amortization
$779K
(-55.36%↓ Y/Y)
Noncash interest
expense
$355K
Noncash lease expense
$242K
(-34.77%↓ Y/Y)
Prepaid expenses and
other assets
-$157K
(-103.06%↓ Y/Y)
Loss (gain) on change
in fair value of...
$118K
(104.77%↑ Y/Y)
Accounts receivable
-$65K
(87.45%↑ Y/Y)
Canceled cashflow
$29,155K
Net cash used in
operating activities
-$21,082K
(48.11%↑ Y/Y)
Net cash used in
investing activities
-$272K
(92.59%↑ Y/Y)
Effect of exchange rate
changes on cash
-$25K
(-156.82%↓ Y/Y)
Canceled cashflow
$28,891K
Research and
development-Descartes08For MG
$12,465K
General and
administrative
$8,724K
Research and
development-Research And Development...
$4,027K
Research and
development-Research And Development...
$2,118K
Research and
development-Early Stage Programs
$971K
Research and
development-Research And Development...
$614K
Research and
development-Descartes08For...
$236K
Gain on change in fair
value of contingent...
-$49,200K
(-38.02%↓ Y/Y)
Purchases of property and
equipment
$272K
(-92.59%↓ Y/Y)
Accounts payable
-$773K
(-434.63%↓ Y/Y)
Back
Back
Cash Flow
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)
source: myfinsight.com